Insights

Strategic Partnerships Genezen's recent collaborations with Humane Genomics and Curebatten highlight its active engagement in advancing oncolytic virus therapies and rare disease treatments, demonstrating opportunities to support innovative target indications and expand service offerings.

Regulatory Expertise With multiple global regulatory licenses including FDA, EMA, Health Canada, and MFDS Korea, Genezen is well-positioned to attract clients seeking compliant, internationally approved viral vector manufacturing, facilitating market expansion for potential partners.

Growth & Recognition Recognized as a Great Place to Work and a Best Places to Work winner, Genezen's strong corporate culture and reputation can serve as compelling selling points when engaging with innovative organizations looking for reliable CDMO partners.

Technological Capabilities Leveraging advanced tools such as Veeva Vault, Benchling, and Microsoft Dynamics, Genezen offers cutting-edge process management and compliance solutions, appealing to research-focused biotech companies prioritizing technological integration.

Financial Stability With a revenue range of $50M to $100M and recent funding of $19M, Genezen demonstrates financial stability and growth potential, making it an attractive partner for companies seeking dependable manufacturing support for their clinical and commercial gene therapies.

Similar companies to Genezen

Genezen Tech Stack

Genezen uses 8 technology products and services including Veeva Vault, Microsoft Dynamics, Benchling, and more. Explore Genezen's tech stack below.

  • Veeva Vault
    Enterprise Content Management
  • Microsoft Dynamics
    Enterprise Resource Planning
  • Benchling
    Health Platform
  • jQuery
    Javascript Libraries
  • Slick
    Javascript Libraries
  • Pardot
    Marketing
  • GoDaddy
    Web Hosting
  • RankMath SEO
    Web Platform Extensions

Media & News

Genezen's Email Address Formats

Genezen uses at least 2 format(s):
Genezen Email FormatsExamplePercentage
FLast@genezenlabs.comJDoe@genezenlabs.com
100%
FLast@genezen.comJDoe@genezen.com
93%
First@genezen.comJohn@genezen.com
4%
FMiddleLast@genezen.comJMichaelDoe@genezen.com
3%

Frequently Asked Questions

What is Genezen's official website and social media links?

Minus sign iconPlus sign icon
Genezen's official website is genezen.com and has social profiles on LinkedInCrunchbase.

What is Genezen's SIC code NAICS code?

Minus sign iconPlus sign icon
Genezen's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Genezen have currently?

Minus sign iconPlus sign icon
As of December 2025, Genezen has approximately 247 employees across 4 continents, including North AmericaAfricaAsia. Key team members include Chief Technical And Commercial Officer: S. D.Chief Operations Officer: M. W.Vice President Of Quality: S. H. M.. Explore Genezen's employee directory with LeadIQ.

What industry does Genezen belong to?

Minus sign iconPlus sign icon
Genezen operates in the Biotechnology Research industry.

What technology does Genezen use?

Minus sign iconPlus sign icon
Genezen's tech stack includes Veeva VaultMicrosoft DynamicsBenchlingjQuerySlickPardotGoDaddyRankMath SEO.

What is Genezen's email format?

Minus sign iconPlus sign icon
Genezen's email format typically follows the pattern of FLast@genezenlabs.com. Find more Genezen email formats with LeadIQ.

How much funding has Genezen raised to date?

Minus sign iconPlus sign icon
As of December 2025, Genezen has raised $19M in funding. The last funding round occurred on Nov 02, 2023 for $19M.

When was Genezen founded?

Minus sign iconPlus sign icon
Genezen was founded in 2014.

Genezen

Biotechnology ResearchIndiana, United States201-500 Employees

Founded in 2014 in Indianapolis, IN, Genezen is a best-in-class gene therapy CDMO with over a decade of experience supporting the cell and gene therapy manufacturing market worldwide. With capabilities across vector-modalities (AAV, lentiviral, retroviral, and others), Genezen partners with innovator organizations to deliver potentially life-saving gene and cell therapies – from concept to commercial. With flexible and customer-centric programs, Genezen tailors its partnership-model approach to all sizes and stages of organizations, to make viral vector production accessible to both early-stage, growth-oriented companies and established industry leaders. Genezen’s state-of-the art Lexington, MA site holds multiple global regulatory licenses, including with the FDA, EMA, Health Canada, and MFDS Korea, in support of the active manufacture of a commercial viral vector-based product. Our Indianapolis, IN site provides cGMP manufacturing for viral vectors and is currently supporting a program entering a pivotal clinical trial.

Section iconCompany Overview

SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2014
Employees
201-500

Section iconFunding & Financials

  • $19M

    Genezen has raised a total of $19M of funding over 1 rounds. Their latest funding round was raised on Nov 02, 2023 in the amount of $19M.

  • $50M$100M

    Genezen's revenue is estimated to be in the range of $50M$100M

Section iconFunding & Financials

  • $19M

    Genezen has raised a total of $19M of funding over 1 rounds. Their latest funding round was raised on Nov 02, 2023 in the amount of $19M.

  • $50M$100M

    Genezen's revenue is estimated to be in the range of $50M$100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.